Vida Ventures, LLC - Feb 7, 2024 Form 3 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role: 10%+ Owner
Signature: Vida Ventures, LLC, By: /s/ Fred Cohen, Director
Stock symbol: KYTX
Transactions as of: Feb 7, 2024
Transactions value $: $0
Form type: 3
Date filed: 2/7/2024, 09:56 PM
Next filing: Feb 14, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Date	Underlying Class	Amount	Ownership	Footnotes
holding	KYTX	Series A-1 Redeemable Convertible Preferred Stock	Feb 7, 2024	Common Stock	967K	Direct	F1, F2
holding	KYTX	Series A-2 Redeemable Convertible Preferred Stock	Feb 7, 2024	Common Stock	1.94M	Direct	F1, F2
holding	KYTX	Series B Redeemable Convertible Preferred Stock	Feb 7, 2024	Common Stock	1.62M	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock has no expiration date and is convertible into the Issuer's Common Stock on a 1-for-4.5511 basis at any time. The number of underlying shares of Common Stock reported in Column 3 reflects an automatic conversion of each outstanding share of Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock into shares of Common Stock at a ratio of 1-for-4.5511 to be effective immediately prior to the closing of the Issuer's initial public offering.
F2	Vida Ventures Advisors, LLC is the investment advisor to the Reporting Person. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by the Reporting Person, but each disclaims beneficial ownership of the shares held by the Reporting Person except to the extent of such person's pecuniary interest therein, if any.

Content

The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock has no expiration date and is convertible into the Issuer's Common Stock on a 1-for-4.5511 basis at any time. The number of underlying shares of Common Stock reported in Column 3 reflects an automatic conversion of each outstanding share of Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock into shares of Common Stock at a ratio of 1-for-4.5511 to be effective immediately prior to the closing of the Issuer's initial public offering.

Vida Ventures Advisors, LLC is the investment advisor to the Reporting Person. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by the Reporting Person, but each disclaims beneficial ownership of the shares held by the Reporting Person except to the extent of such person's pecuniary interest therein, if any.